NCT04896112 is a Phase 1 clinical trial of LNK01002 in Acute Myeloid Leukemia, sponsored by Lynk Pharmaceuticals Co., Ltd.

Who is sponsoring NCT04896112?

NCT04896112 is sponsored by Lynk Pharmaceuticals Co., Ltd.

What drugs are being tested in NCT04896112?

Interventions in NCT04896112: LNK01002.

What condition does NCT04896112 study?

NCT04896112 studies Acute Myeloid Leukemia, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera.

Is NCT04896112 still recruiting?

NCT04896112 is currently withdrawn. Last updated 18 June 2023.

Last reviewed 2023-06-18 · How we verify

NCT04896112

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of LNK01002 in Patients With Primary or Secondary Myelofibrosis,Polycythemia Vera or Acute Myeloid Leukemia

Withdrawn Phase 1 Last updated 18 June 2023

What this trial tests

Phase 1 trial testing LNK01002 in Acute Myeloid Leukemia. Withdrawn.

Timeline

8 April 2021

Primary endpoint
20 October 2022

20 October 2022

Quick facts

Lead sponsor	Lynk Pharmaceuticals Co., Ltd
Phase	Phase 1
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Start date	8 April 2021
Primary completion	20 October 2022
Estimated completion	20 October 2022
Sites	2 locations across United States

Drugs / interventions tested

LNK01002 — full drug profile →

Conditions studied

Acute Myeloid Leukemia — all drugs for Acute Myeloid Leukemia →
Primary Myelofibrosis — all drugs for Primary Myelofibrosis →
Post-polycythemia Vera Myelofibrosis — all drugs for Post-polycythemia Vera Myelofibrosis →
Post-essential Thrombocythemia Myelofibrosis — all drugs for Post-essential Thrombocythemia Myelofibrosis →

Sponsor

Lynk Pharmaceuticals Co., Ltd — full company profile →

Who can join

Adults 18 to 99, any sex, with Acute Myeloid Leukemia or Primary Myelofibrosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This multicenter, open-label, phase 1 study designed to evaluate safety and tolerability of multi-kinase inhibitor LNK01002 in patients with primary myelofibrosis (PMF), or MF due to polycythemia vera (PV-MF), or essential thrombocythemia (ET-MF), polycythemia vera (PV), or with acute myeloid leukemia (AML).

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Progression of Myeloproliferative Neoplasms (MPN): Diagnostic and Therapeutic Perspectives.
Baumeister J, Chatain N, Sofias AM, Lammers T, et al · · 2021 · cited 50× · PMID 34944059 · DOI 10.3390/cells10123551
Protein degradation: expanding the toolbox to restrain cancer drug resistance.
Ming H, Li B, Jiang J, Qin S, et al · · 2023 · cited 42× · PMID 36694209 · DOI 10.1186/s13045-023-01398-5
Novel approaches to targeted protein degradation technologies in drug discovery.
Xue Y, Bolinger AA, Zhou J. · · 2023 · cited 34× · PMID 36895136 · DOI 10.1080/17460441.2023.2187777
Proteolysis-targeting chimeras in cancer therapy: Targeted protein degradation for next-generation treatment.
Anaya YA, Barragan M, Bracho RP, Shaham SH, et al · · 2025 · cited 3× · PMID 41108678 · DOI 10.1002/cncr.70132
Targeted protein degradation with small molecules for cancer immunotherapy.
Yang Z, Xu J, Yang X, Chen J. · · 2025 · cited 3× · PMID 40791660 · DOI 10.1016/j.ajps.2025.101058

Verify or expand the search:

Other recruiting trials for Acute Myeloid Leukemia

Currently open trials in the same condition.

NCT07020533 — A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Pa · Phase 1 · recruiting
NCT06782542 — Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for I · Phase 2 · recruiting
NCT07177079 — High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML · Phase 1 · recruiting
NCT07384715 — First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelod · Phase 1 · recruiting
NCT07107126 — Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes · Phase 1 · recruiting

Other Lynk Pharmaceuticals Co., Ltd trials

Trials by the same sponsor.

NCT07071610 — A Study to Evaluate the Efficacy and Safety of LNK01004 Ointment in Adults With Atopic Dermatitis · Phase 2 · completed
NCT06277245 — A Phase 3 Study of LNK01001 Capsule in Subjects With Moderate to Severe Atopic Dermatitis. · Phase 3 · completed
NCT06276998 — A Study of LNK01001 Capsule in Subjects With Active Rheumatoid Arthritis (COURAGE-RA) · Phase 3 · active not recruiting
NCT06553287 — Safety, Tolerability and Pharmacokinetics of LNK01004 Ointment in Adults With Atopic Dermatitis. · Phase 1 · completed
NCT06085521 — A Study of LNK01001 Capsule in Patients With Moderate to Severe Atopic Dermatitis · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04896112 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Lynk Pharmaceuticals Co., Ltd
Last refreshed: 18 June 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04896112.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing